A role of human beta defensin-1 in predicting prostatic adenocarcinoma in cases of false-negative biopsy

被引：7
作者：
Hong, Soon Auck [1 ]
Kim, Ki Hong [2 ]
Lee, Tae Jin [3 ]
Park, Eon Sub [3 ]
Kim, Mi Kyung [3 ]
Myung, Soon Chul [4 ]
机构：
[1] Soonchunhyang Univ, Cheonan Hosp, Dept Pathol, Cheonan, South Korea
[2] Soonchunhyang Univ, Cheonan Hosp, Dept Urol, Cheonan, South Korea
[3] Chung Ang Univ, Coll Med, Chung Ang Univ Hosp, Dept Pathol, Seoul, South Korea
[4] Chung Ang Univ, Coll Med, Chung Ang Univ Hosp, Dept Urol, 224-1 Heukseok Dong, Seoul 156755, South Korea
来源：
APMIS | 2017年 / 125卷 / 12期
基金：
新加坡国家研究基金会;
关键词：
Human beta defensin-1; prostate adenocarcinoma; immunohistochemistry; false negative; repeat biopsy;
D O I：
10.1111/apm.12749
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The purpose of this study was to clarify the role of human beta defensin-1 (hBD-1) in predicting PAC in morphologically normal prostate glands. In total, 25 patients with a negative initial biopsy for PAC and diagnosed as PAC positive in subsequent biopsies performed within 1 year of the initial biopsy were included. As a control group, 22 patients negative for PAC in at least three consecutive histologic examinations were selected. Expression of hBD-1 was analyzed separately via immunohistochemistry in paired cores of non-neoplastic gland and PAC in the false-negative group and control group. Loss of hBD-1 expression was observed in 95.6% and 90.0% PAC cases with Gleason Patterns 3 and 4 in repeat biopsies, respectively. hBD-1 loss of basal cells in 40 (85.1%) previous non-neoplastic biopsy cores in the false-negative group was observed, in contrast to preserved basal cell expression of hBD-1 in 64 (72.7%) biopsy cores in the control group (p = 0.001). Multivariate logistic regression analysis showed that hBD-1 basal cell loss (20% of prostatic glands in total cores) is an independent factor for predicting PAC (odds ratio: 4.739, confidence interval: 1.093-20.554, p = 0.038). hBD-1 loss of basal cells is a useful indicator to identify extremely high-risk patients with initially negative biopsy.
引用
收藏
页码：1063 / 1069
页数：7
相关论文
共 33 条
  • [1] Torre L.A., Siegel R.L., Ward E.M., Jemal A., Global cancer incidence and mortality rates and trends-an update, Cancer Epidemiol Biomarkers Prev, 25, pp. 16-27, (2016)
  • [2] Roberts R.O., Bergstralh E.J., Lieber M.M., Jacobsen S.J., Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997, Urology, 56, pp. 817-822, (2000)
  • [3] Moyer V.A., Screening for prostate cancer: US Preventive Services Task Force recommendation statement, Ann Intern Med, 157, pp. 120-134, (2012)
  • [4] Wolters T., van der Kwast T.H., Vissers C.J., Bangma C.H., Roobol M., Schroder F.H., Et al., False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up, Am J Surg Pathol, 34, pp. 35-43, (2010)
  • [5] Gann P.H., Fought A., Deaton R., Catalona W.J., Vonesh E., Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach, J Clin Oncol, 28, pp. 1714-1720, (2010)
  • [6] Fleshner N.E., O'sullivan M., Fair W.R., Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate, J Urol, 158, pp. 505-509, (1997)
  • [7] Satoh A., Matsumoto K., Nakamura S., Is interval from an initial biopsy a significant predictor of prostate cancer at repeat biopsies?, Int J Urol, 13, pp. 224-227, (2006)
  • [8] Keetch D., Catalona W., Smith D., Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values, J Urol, 151, pp. 1571-1574, (1994)
  • [9] Papo N., Shai Y., Host defense peptides as new weapons in cancer treatment, Cell Mol Life Sci, 62, pp. 784-790, (2005)
  • [10] Yang D., Chertov O., Bykovskaia S., Chen Q., Buffo M., Shogan J., Et al., β-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6, Science, 286, pp. 525-528, (1999)
1234